Search PubMed⌕ Search

Biomedical subjects

L Mantovani

Publications and source records attributed to L Mantovani.

57 records · Page 4Linked to original sources
PubMedDate not supplied

A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas.

From September, 1984 to July, 1986 seventy previously untreated adult patients with advanced non-Hodgkin's lymphoma of intermediate or high grade histology were enrolled in an open phase III multicenter, comparative chemotherapeutic trial. The objectives were to compare, by means of response rate, duration of response and survival time, the efficacy and safety of substituting mitoxantrone for doxorubicin in the combination chemotherapy regimen m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone). Thirty-five patients were randomly assigned to receive m-B-NOVANTRONE TM (mitoxantrone)-COD (m-BNCOD) and 35 m-B-ADRIAMYCIN TM (doxorubicin)-COD. The complete response rate was 57% for both treatment groups, and no significant disease-free survival and survival differences were found between the two groups of patients. Patients treated with m-BACOD experienced severe alopecia more frequently (p less than 0.001) and, after 10 cycles, six adverse cardiac event of WHO grade greater than 1, as opposed to none among those who received m-BNCOD. The mitoxantrone-containing regimen (m-BNCOD) has equivalent efficacy and reduced toxicity compared to the standard doxorubicin-containing regimen (m-BACOD) in patients with poor prognosis NHL.

Adult↗
PubMedDate not supplied

Recombinant alpha interferon in the treatment of low-grade non-Hodgkin's lymphoma: results of a cooperative phase II trial in 31 patients.

Thirty-one patients with advanced stage of favorable histology non-Hodgkin's lymphomas were entered into a multicenter phase II trial with recombinant alpha A interferon as single agent. Interferon was administered intramuscular in doses of 6 x 10(6)/IU/m2 three times per week for 12 weeks. Dose escalation was applied, in the absence of toxicities greater than WHO grade II, in patients not responding after 4 weeks. In responding patients treatment was continued at the same dose with a weekly maintenance schedule for 12 additional weeks. Objective responses (4 complete, 10 partial) were obtained in 14 of the 27 evaluable patients (52%). Median time to progression was 15 months for partial responders, while none of the complete responders has relapsed up to the present time. Toxicity was generally moderate and manageable. Treatment was discontinued in three patients because of side effects, and one patient refused therapy after 3 weeks. Our study shows that recombinant alpha A interferon has antitumor activity in patients with favorable histology non-Hodgkin's lymphoma.

Adult↗